GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.

HanesBrands has disclosed the departure of its CEO who is set to step down by the end of 2025 or upon the naming of a ...

Crocs has delivered a solid performance for fiscal year 2024 (FY24) with consolidated revenues reaching $4.1bn from $3.96bn ...

Cellebrite DI (CLBT) reported its fourth-quarter and full-year 2024 earnings, revealing a revenue of $109 million for Q4, surpassing expectations with an EPS of $0.08 against a forecast of $0.06. The ...

Q4 sales & FY 2024 resultsSales & Ebita margin in line with revised guidance 2024; FCF conversion exceeding objective Positive North ...

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 PatientsSHIELD II Enrolled more than ...

The return starts with total income and then deductions and other expenses are subtracted to arrive at adjusted gross income (AGI). Itemized deductions and expenses reduce AGI to calculate the tax ...

Adjusted operating income for the quarter totaled US$334 million, or US$4.99 per diluted share, compared to US$316 million, or US$4.73 per diluted share, a year earlier. Excluding notable items ...

The company has adjusted the half-year accounts to reflect the impact of this described operation and is publishing its adjusted results for the first half of 2024. First half 2024 results before ...

QIAGEN N.V.’s QGEN fourth-quarter 2024 adjusted earnings per share (EPS) were 61 cents, the same at the constant exchange rate (CER). The reported figure increased 11% from the 2023 comparable figure.